- Home
- RDN vs AKRO Comparison
RDN vs AKRO Comparison
Compare RDN & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDN
- AKRO
- Stock Information
- Founded
- RDN 1977
- AKRO 2017
- Country
- RDN United States
- AKRO United States
- Employees
- RDN N/A
- AKRO N/A
- Industry
- RDN Property-Casualty Insurers
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- RDN Finance
- AKRO Health Care
- Exchange
- RDN Nasdaq
- AKRO Nasdaq
- Market Cap
- RDN 4.6B
- AKRO 3.9B
- IPO Year
- RDN 1992
- AKRO 2019
- Fundamental
- Price
- RDN $33.84
- AKRO $51.69
- Analyst Decision
- RDN Hold
- AKRO Strong Buy
- Analyst Count
- RDN 7
- AKRO 6
- Target Price
- RDN $36.57
- AKRO $82.50
- AVG Volume (30 Days)
- RDN 1.4M
- AKRO 1.6M
- Earning Date
- RDN 07-30-2025
- AKRO 08-08-2025
- Dividend Yield
- RDN 2.98%
- AKRO N/A
- EPS Growth
- RDN 4.01
- AKRO N/A
- EPS
- RDN 3.92
- AKRO N/A
- Revenue
- RDN $1,288,979,000.00
- AKRO N/A
- Revenue This Year
- RDN N/A
- AKRO N/A
- Revenue Next Year
- RDN $2.30
- AKRO N/A
- P/E Ratio
- RDN $8.63
- AKRO N/A
- Revenue Growth
- RDN 3.11
- AKRO N/A
- 52 Week Low
- RDN $29.32
- AKRO $21.34
- 52 Week High
- RDN $37.86
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- RDN 40.51
- AKRO 45.35
- Support Level
- RDN $35.38
- AKRO $50.13
- Resistance Level
- RDN $36.81
- AKRO $53.60
- Average True Range (ATR)
- RDN 0.70
- AKRO 2.03
- MACD
- RDN -0.28
- AKRO -0.83
- Stochastic Oscillator
- RDN 4.54
- AKRO 6.37
About RDN Radian Group Inc.
Radian Group Inc is engaged in mortgage and real estate services. It provides both credit-related mortgage insurance coverage and other products and services across the residential real estate and mortgage finance industries. It has one business segment Mortgage Insurance. The Mortgage Insurance segment aggregates, manages, and distributes U.S. mortgage credit risk for the benefit of mortgage lending institutions and mortgage credit investors, through private mortgage insurance on residential first-lien mortgage loans, and also offers other credit risk management solutions, including contract underwriting, to customers. It also provides other mortgage and real estate products and services through Mortgage Conduit, Title, Real Estate Services, and Real Estate Technology businesses.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.